Confirmation of Change in ADS Ratio

AstraZeneca PLC (the "Company") today confirmed that the intended ratio change
to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR")
programme announced on 26 June 2015 has now become effective. With effect from
27 July 2015, the Company's American Depositary Share ("ADS") ratio is two (2)
ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1)
Ordinary Share. There are no changes to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July
2015, received a distribution of one additional ADS for every ADS held. No
action was required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depositary, can be found
below.

A C N Kemp
Company Secretary
27 July 2015



CONTACT

Citibank Shareholder Services



PO Box 43077    Tel (toll free in the US): +1-888-697-8018
Providence      Tel (outside the US): +1-781-575-4555
 RI 02940-3077
 US



Media Enquiries

Esra Erkal-Paler  +44 20 7604 8030 (UK/Global)
Jacob Lund        +46 8 553 260 20 (Sweden)
Michele Meixell   + 1 302 885 6351 (US)

Investor Enquiries

UK
Thomas                                  +44 20 7604 8199  mob: +44 7818 524185
Kudsk
Larsen
Eugenia    Respiratory, Inflammation    +44 20 7604 8233  mob: +44 7884 735627
Litz       and Autoimmunity
Nick       Cardiovascular andMetabolic  +44 1763 263 994  mob: +44 7717 618834
Stone      Disease
Karl Hård  Oncology                     +44 20 7604 8123  mob: +44 7789 654364
Craig      Infection, Neuroscience and  +44 20 7604 8591  mob: +44 7881 615764
Marks      Gastrointestinal   Disease
Christer                                +44 20 7604 8126  mob: +44 7827 836825
Gruvris
US
Dial /                                  301-398-3251       866-381-7277
Toll-Free